UPMC Hillman Cancer Center

Hassane M. Zarour, MD

Hassane Zarour
Professor of Medicine, Immunology and Dermatology
Co-Leader, Hillman Melanoma Program

Contact Information

Contact Information

Hillman Cancer Center, Research Pavilion
5117 Centre Avenue
Lab 1.32a
Pittsburgh, PA 15213

Phone: 412-623-3244
Email: zarourhm@upmc.edu

Administrative Assistant
Name: Gina Toy-Cutler
Phone: 412-623-3241
Email: toyg@upmc.edu
Fax: 412-623-7704

Research Keywords

Research Keywords

Cancer immunology; cancer immunotherapy; melanoma; skin cancer

Research Summary

Research Summary

Hassane Zarour, MD is a dermatologist and cancer immunologist whose research focuses on basic and translational human cancer immunology in the melanoma field. His work has led to the identification of novel melanoma MHC class II-presented epitopes that have been used in investigator-initiated trials at UPMC Hillman Cancer Center as well as in multi-center trials. Most recently, Dr. Zarour’s work has contributed to elucidating the role of inhibitory receptors in promoting melanoma-induced T cell dysfunction in the tumor microenvironment. These findings led to the development of novel antibodies targeting inhibitory receptors for clinical trials. Dr. Zarour actively contributes to the design and the implementation of novel investigator-initiated trials based on laboratory findings, including two melanoma vaccine trials funded by the Cancer Research Institute and the National Cancer Institute, respectively. He is the lead scientific investigator on the Hillman Skin Cancer SPORE Project 3 that is testing the novel combination of BRAF inhibitor (BRAFi) therapy with high-dose interferon for metastatic V600E positive melanoma. He is also testing a novel combination of an anti-PD-1 antibody (MK 3475/Pembrolizumab) and PEG-interferon with grant support from an academic-industry award of the Melanoma Research Alliance.

Selected Publications

Selected Publications

  • Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, Zarour HM. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015 May;125(5):2046-58. PubMed Link
  • Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, Zarour HM. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 2015 Apr 15;75(8):1635-44. PubMed Link
  • Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109-17. PubMed Link
  • Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15;74(4):1045-55. PubMed Link
  • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11;369(2):134-44. PubMed Link
  • Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012 Feb 15;72(4):887-96. PubMed Link
  • Fourcade J, Sun Z, Benalloua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010 Sep 27;207(10):2175-86. PubMed Link
  • Fourcade J, Sun Z, Kudela P, Janjic B, Kirkwood JM, El-Hafnawy T, Zarour HM. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol. 2010 Jun 15;184(12):6709-18. PubMed Link
  • Fourcade J, Kudela P, Sun Z, Shen H, Land S, Lenzner D, Guillaume P, Luescher I, Sander C, Ferrone S, Kirkwood J, Zarour HM. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 1;182(9):5240-9. PubMed Link
  • Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analogue peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct;31(8):781-91. PubMed Link

See all pubs (Pubmed)

Collaborations

Collaborations

Current Internal Collaborators

John Kirkwood, MD
Sandra and Thomas Usher Endowed Chair and Professor of Medicine
Co-Leader - Melanoma Program (MP)

James Lee, MD, PhD
Associate Professor of Medicine
Member - Cancer Therapeutics Program (CTP)

Current External Collaborators

Vijay Kuchroo, PhD
Professor of Neurology
Harvard Medical School

Daniel Olive, MD, PhD
Professor of Immunology
University of Marseille Medical School, France

Shared Resource Usage

Shared Resource Usage

  • Biostatistics Facility
  • Cancer Bioinformatics Services
  • Cancer Genomics Facility
  • Cancer Proteomics Facility
  • Cell and Tissue Imaging Facility
  • Cytometry Facility
  • IMCPL
  • Tissue and Research Pathology Services

Department Website









Last modified: 8/1/17